John L. Lamattina - 07 Nov 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Andrew Reardon, Attorney-in-Fact For: John L. LaMattina
Issuer symbol
LGND
Transactions as of
07 Nov 2025
Net transactions value
-$575,343
Form type
4
Filing time
12 Nov 2025, 16:44:42 UTC
Previous filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LAMATTINA JOHN L Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: Andrew Reardon, Attorney-in-Fact For: John L. LaMattina 12 Nov 2025 0001216074

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $141,849 +2,145 +7% $66.13 32,869 07 Nov 2025 Direct
transaction LGND Common Stock Sale $440,690 -2,145 -6.5% $205.45 30,724 07 Nov 2025 Direct
transaction LGND Common Stock Options Exercise $141,383 +2,034 +6.6% $69.51 32,758 07 Nov 2025 Direct
transaction LGND Common Stock Sale $417,885 -2,034 -6.2% $205.45 30,724 07 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,145 -100% $0.000000 0 07 Nov 2025 Common Stock 2,145 $66.13 Direct F1
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,034 -100% $0.000000 0 07 Nov 2025 Common Stock 2,034 $69.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 2,456 shares, which vested in full on May 25, 2018, at an exercise price of $113.5000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F2 This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.